See also:
What is the most important information I should know about Chlorhexidine Gluconate (Rexidin M FORTE)?
You should not use this medication if you are allergic to Chlorhexidine Gluconate (Rexidin M FORTE).
If you have periodontal disease, you may need special treatments while you are using Chlorhexidine Gluconate (Rexidin M FORTE).
Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse is not for treating all types of gingivitis. Use the medication only to treat the condition your dentist prescribed it for. Do not share this medication with another person, even if they have the same gum symptoms you have.
Do not give this medication to a child or teenager without a doctor's advice.
Do not add water to Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse. Do not rinse your mouth with water or other mouthwashes right after using Chlorhexidine Gluconate (Rexidin M FORTE).
Avoid eating, drinking, or brushing your teeth just after using this medication.
Do not use any other mouthwash unless your doctor has told you to.
Chlorhexidine Gluconate (Rexidin M FORTE) can stain teeth, dentures, tooth restorations, your tongue, or the inside of your mouth. Talk with your dentist about ways to remove staining from these surfaces. Stains may be harder to remove from false teeth that have scratches in their surfaces.
Visit your dentist at least every 6 months for preventive tooth and gum care.
See also:
What is the most important information I should know about Lidocaine Topical (Rexidin M FORTE)?
An overdose of numbing medications can cause fatal side effects if too much of the medicine is absorbed through your skin and into your blood. This is more likely to occur when using a numbing medicine without the advice of a medical doctor (such as during a cosmetic procedure like laser hair removal). However, overdose has also occurred in women treated with a numbing medicine before having a mammography. Overdose symptoms may include uneven heartbeats, seizure (convulsions), coma, slowed breathing, or respiratory failure (breathing stops).
Your body may absorb more of this medication if you use too much, if you apply it over large skin areas, or if you apply heat, bandages, or plastic wrap to treated skin areas. Skin that is cut or irritated may also absorb more topical medication than healthy skin.
Use the smallest amount of this medication needed to numb the skin or relieve pain. Do not use large amounts of Lidocaine Topical (Rexidin M FORTE), or cover treated skin areas with a bandage or plastic wrap without medical advice. Be aware that many cosmetic procedures are performed without a medical doctor present.
Keep both used and unused lidocaine skin patches out of the reach of children or pets. The amount of lidocaine in the skin patches could be harmful to a child or pet who accidentally sucks on or swallows the patch. Seek emergency medical attention if this happens.
See also:
What is the most important information I should know about Metronidazole Topical (Rexidin M FORTE)?
Do not use Metronidazole Topical (Rexidin M FORTE) if you have ever had an allergic reaction to it.
Before using Metronidazole Topical (Rexidin M FORTE), tell your doctor if you are allergic to any drugs, or if you have a blood cell disorder such as anemia or decreased white blood cells.
Tell your doctor about all other medications you use, especially a blood thinner such as warfarin (Coumadin).
Metronidazole Topical (Rexidin M FORTE) is for use only on the skin. Avoid getting this medication in your eyes. If this does happen, rinse thoroughly with cool water. Do not use topical metronidazole in the vagina.
Call your doctor if you have severe stinging or burning when you apply Metronidazole Topical (Rexidin M FORTE).
Use this medication for the entire length of time prescribed by your doctor. Your symptoms may get better before any infection is completely treated. Do not use Metronidazole Topical (Rexidin M FORTE) to treat any other skin infection your doctor has not prescribed it for.
See also:
What are the possible side effects of Chlorhexidine Gluconate (Rexidin M FORTE)?
The most common side effects associated with Chlorhexidine Gluconate (Rexidin M FORTE) oral rinses are (1) an increase in staining of teeth and other oral surfaces, (2) an increase in calculus formation; and (3) an alteration in taste perception; see WARNINGS and PRECAUTIONS.
Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with the use of Chlorhexidine Gluconate (Rexidin M FORTE) rinse.
The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%.
Among post marketing reports, the most frequently reported oral mucosal symptoms associated with Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia.
Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse.
There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse.
See also:
What are the possible side effects of Lidocaine Topical (Rexidin M FORTE)?
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Lidocaine Topical (Rexidin M FORTE)™ has been evaluated in 10 clinical trials, five in adults and five in pediatric patients.
The five adult clinical trials consisted of a randomized, double-blind, parallel-arm, sham-placebo controlled Phase 3 trial that enrolled 693 patients, two randomized, double-blind, crossover design, sham-placebo controlled Phase 1 trials that enrolled 455 patients, and two open-label studies that enrolled 44 patients. A total of 742 adults received an active treatment with an active treatment that delivered a 0.5 mg dose of lidocaine, while 775 received placebo.
The five pediatric clinical trials consisted of five randomized, double-blind, parallel-arm, sham-placebo controlled trials in which 1761 patients, ages 3 to 18, received either Lidocaine Topical (Rexidin M FORTE)™ or a sham placebo device. A total of 906 pediatric patients received active treatment, while 855 received placebo.
Application Site Reaction
The application site was specifically assessed for four categories of skin site reaction (erythema, edema, pruritus, and petechiae).
In adults, erythema occurred in 67.3% of Lidocaine Topical (Rexidin M FORTE)™-treated patients, and in 25.0% of placebo-treated patients. Petechiae occurred in 46.4% of Lidocaine Topical (Rexidin M FORTE)™-treated patients, and in 7.0% of placebo-treated patients. Edema occurred in 4.3% of Lidocaine Topical (Rexidin M FORTE)™-treated patients, and in 0.8% of placebo-treated patients. Pruritus occurred in 9.4% of Lidocaine Topical (Rexidin M FORTE)™-treated patients and in 6.2% of placebo-treated patients.
In pediatric patients, erythema occurred in 53% of Lidocaine Topical (Rexidin M FORTE)-treated patients, and in 27% of placebo-treated patients. Petechiae occurred in 44% of Lidocaine Topical (Rexidin M FORTE)-treated patients, and in 5% of placebo-treated patients. Edema occurred in 8% of Lidocaine Topical (Rexidin M FORTE)-treated patients, and in 3% of placebo-treated patients. Pruritus occurred in 1% of patients in both treatment groups.
Adverse Reactions
Amongst the 742 adult patients receiving active treatment and 775 adult patients receiving sham placebo treatment in the 5 adult studies, the percentage of adult patients with any adverse reactions was 3.9% in the active-treated patients and 4.9% in the sham placebo treated patients.
Most adverse reactions were application-site related (i.e., hypoaesthesia (0% active, 0.5% sham placebo), burning (0.54% active, 0.4% sham placebo), and venipuncture site hemorrhage (0.4% active, 1.7% sham placebo)).
The most common systemic adverse reaction was dizziness, which occurred in 0.9% of active-treated adult patients and in 0.7% of sham placebo treated adult patients. No other systemic adverse events occurred in more than two patients in either treatment group.
Amongst the 906 pediatric patients receiving active treatment and 855 pediatric patients receiving sham placebo treatment, the percentage of pediatric patients with any adverse reactions was approximately 9% in each treatment group.
Most adverse reactions were application-site related (i.e., bruising, burning, pain, contusion, hemorrhage), occurring in 4% of pediatric patients in each treatment group.
The most common systemic adverse reactions were nausea (2%) and vomiting (1%).
See also:
What are the possible side effects of Metronidazole Topical (Rexidin M FORTE)?
In a controlled clinical trial, safety data from 141 patients who used Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion (n=71), or the lotion vehicle (n=70), twice daily and experienced a local cutaneous adverse event which may or may not have been related to the treatments include: local allergic reaction, Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion 2 (3%), lotion vehicle 0; contact dermatitis, Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion 2 (3%), lotion vehicle 1 (1%); pruritus, Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion 1 (1%), lotion vehicle 0; skin discomfort (burning and stinging), Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion 1 (1%), lotion vehicle 2 (3%); erythema, Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion 4 (6%), lotion vehicle 0; dry skin, Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion 0, lotion vehicle 1 (1%); and worsening of rosacea, Metronidazole Topical (Rexidin M FORTE)® (metronidazole lotion)
Topical Lotion 1 (1%), lotion vehicle 7 (10%). The following additional adverse experiences have been reported with the topical use of metronidazole: skin irritation, transient redness, metallic taste, tingling or numbness of extremities, and nausea.
Chlorhexidine Gluconate (Rexidin M FORTE)® (Chlorhexidine Gluconate (Rexidin M FORTE)
Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine Gluconate (Rexidin M FORTE)® has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Lidocaine Topical (Rexidin M FORTE)™ (lindocaine hydrochloride monohydrate) is indicated for use on intact skin to provide topical local analgesia prior to venipuncture or peripheral intravenous cannulation, in children 3–18 years of age.
Lidocaine Topical (Rexidin M FORTE)™ (lindocaine hydrochloride monohydrate) is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Metronidazole Topical (Rexidin M FORTE) is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis).
NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a &ldqou;fishy&rdqou; amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells.
Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus should be ruled out.
Chlorhexidine Gluconate (Rexidin M FORTE) is a germicidal mouthwash that reduces bacteria in the mouth.
Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse is used to treat gingivitis (swelling, redness, bleeding gums). Chlorhexidine Gluconate (Rexidin M FORTE) is usually prescribed by a dentist.
Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse is not for treating all types of gingivitis. Use the medication only to treat the condition your dentist prescribed it for. Do not share this medication with another person, even if they have the same gum symptoms you have.
Chlorhexidine Gluconate (Rexidin M FORTE) may also be used for purposes not listed in this medication guide.
Lidocaine Topical (Rexidin M FORTE) is a local anesthetic (numbing medication). It works by blocking nerve signals in your body.
Lidocaine Topical (Rexidin M FORTE) is used to relieve post-shingles pain. Apply Lidocaine Topical (Rexidin M FORTE) only to intact skin with no blisters.
Lidocaine Topical (Rexidin M FORTE) in other formulations is used to reduce pain or discomfort caused by skin irritations such as sunburn, insect bites, poison ivy, poison oak, poison sumac, and minor cuts, scratches, hemorrhoids, and burns. Lidocaine Topical (Rexidin M FORTE) can also be used to treat sores inside the mouth, during dental procedures to numb the gums, and to numb the skin for a medical procedure (such as getting stiches).
Metronidazole is an antibiotic that fights bacteria in the body.
Metronidazole Topical (Rexidin M FORTE) (for the skin) is used to treat skin lesions caused by rosacea.
Metronidazole Topical (Rexidin M FORTE) may also be used for other purposes not listed in this medication guide.
Each chip contains Chlorhexidine Gluconate (Rexidin M FORTE) 2.5 mg in a biodegradable matrix of hydrolyzed gelatin (cross-linked with glutaraldehyde).
Chlorhexidine Gluconate (Rexidin M FORTE) also contains glycerin and purified water as excipients.
Chlorhexidine Gluconate (Rexidin M FORTE), an antimicrobial agent, is 1, 1'-hexamethylenebis [5-(p-chlorophenyl)biguanide] di-D-gluconate. Molecular Formula: C22H30Cl2N10·2C6H12O7. Molecular Weight: 897.8.
A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine.
A nitroimidazole used to treat amebiasis; vaginitis; trichomonas infections; giardiasis; anaerobic bacteria; and treponemal infections. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed).
Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Rinse your mouth with Chlorhexidine Gluconate (Rexidin M FORTE) twice daily after brushing your teeth.
Measure your dose using the cup provided with the medication. Swish the medicine in your mouth for at least 30 seconds, then spit it out. Do not swallow the mouthwash.
Do not add water to the oral rinse. Do not rinse your mouth with water or other mouthwashes right after using Chlorhexidine Gluconate (Rexidin M FORTE).
Chlorhexidine Gluconate (Rexidin M FORTE) may leave an unpleasant taste in your mouth. Do not rinse your mouth to remove this taste after using the medication. You may rinse the medicine away and reduce its effectiveness.
Use this medication for the full prescribed length of time. Your symptoms may improve before your gingivitis is completely cleared. Chlorhexidine Gluconate (Rexidin M FORTE) will not treat a viral or fungal infection such as cold sores, canker sores, or oral thrush (yeast infection).
Visit your dentist at least every 6 months for preventive tooth and gum care.
Store Chlorhexidine Gluconate (Rexidin M FORTE) at room temperature away from moisture and heat.
Use Lidocaine Topical (Rexidin M FORTE) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Lidocaine Topical (Rexidin M FORTE).
Use Metronidazole Topical (Rexidin M FORTE) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Metronidazole Topical (Rexidin M FORTE).
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Use: Labeled IndicationsGingivitis:
Oral rinse: Antimicrobial dental rinse for gingivitis treatmentPeriodontitis: Periodontal chip: Adjunctive therapy to scaling and root planning procedures to reduce pocket depth in patients with periodontitis
Off Label UsesMedication-related osteonecrosis of the jaw (MRONJ), adjunctive therapy:Oral rinse:
Based on a position paper by the American Association of Maxillofacial Surgeons (AAOMS), Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse is an effective and recommended adjunctive treatment strategy in the management of medication-related osteonecrosis of the jaw (MRONJ) (stage 1 and above [eg, patients with exposed and necrotic bone or fistulae that probes to bone]).
Oropharyngeal decontamination to reduce the risk of ventilator-associated or hospital-acquired pneumonia, Cardiac surgical patients:Oral rinse:Data from a prospective, randomized, double-blind, placebo-control trial and a prospective, randomized, case-controlled trial in patients undergoing coronary artery bypass grafting, valve, or other open heart surgical procedures who received Chlorhexidine Gluconate (Rexidin M FORTE) 0.12% oral rinse during the perioperative period showed a decreased rate in hospital-acquired pneumonia. However, the trials used in both meta-analyses were heterogeneous and included patients in a variety of settings (eg, cardiothoracic, general ICU, mixed medical-surgical ICU, trauma ICU). The trials also displayed significant variability with Chlorhexidine Gluconate (Rexidin M FORTE) treatment regimens. Chlorhexidine Gluconate (Rexidin M FORTE) concentration varied from 0.12%, 0.2%, or 2% across studies. Frequency of administration, Chlorhexidine Gluconate (Rexidin M FORTE) dosage form (oral rinse, gel, paste, foam), and technique of application also varied across studies. In the US, Chlorhexidine Gluconate (Rexidin M FORTE) for use in the oral cavity is commercially available only as 0.12% solution. Additional trials may be necessary to further define the role of Chlorhexidine Gluconate (Rexidin M FORTE) oral rinse in this condition.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.
How to use Lidocaine Topical (Rexidin M FORTE) (acetaminophen)Take this product by mouth as directed. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.
There are many brands and forms of acetaminophen available. Read the dosing instructions carefully for each product because the amount of acetaminophen may be different between products. Do not take more acetaminophen than recommended.
If you are giving acetaminophen to a child, be sure you use a product that is meant for children. Use your child's weight to find the right dose on the product package. If you don't know your child's weight, you can use their age.
For suspensions, shake the medication well before each dose. Some liquids do not need to be shaken before use. Follow all directions on the product package. Measure the liquid medication with the provided dose-measuring spoon/dropper/syringe to make sure you have the correct dose. Do not use a household spoon.
For rapidly-dissolving tablets, chew or allow to dissolve on the tongue, then swallow with or without water. For chewable tablets, chew thoroughly before swallowing.
Do not crush or chew extended-release tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.
For effervescent tablets, dissolve the dose in the recommended amount of water, then drink.
Pain medications work best if they are used as the first signs of pain occur. If you wait until the symptoms have worsened, the medication may not work as well.
Do not take this medication for fever for more than 3 days unless directed by your doctor. For adults, do not take this product for pain for more than 10 days (5 days in children) unless directed by your doctor. If the child has a sore throat (especially with high fever, headache, or nausea/vomiting), consult the doctor promptly.
Tell your doctor if your condition persists or worsens or if you develop new symptoms. If you think you may have a serious medical problem, get medical help right away.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Metronidazole Topical (Rexidin M FORTE) is used to treat rosacea (enlarged facial blood vessels that cause papules, pustules, and swelling). It is also used to treat bacterial infections of the vagina.
One Chlorhexidine Gluconate (Rexidin M FORTE) is inserted into a periodontal pocket with probing pocket depth (PD) 5 mm or greater. Up to 8 chips may be inserted in a single visit. Treatment is recommended to be administered once every three months in pockets with PD remaining 5 mm or greater. The periodontal pocket should be isolated and the surrounding area dried prior to chip insertion.
The Chlorhexidine Gluconate (Rexidin M FORTE) should be grasped using forceps (such that the rounded end points away from the forceps) and inserted into the periodontal pocket to its maximum depth. If necessary, the Chlorhexidine Gluconate (Rexidin M FORTE) can be further maneuvered into position using the tips of the forceps or a flat instrument. The Chlorhexidine Gluconate (Rexidin M FORTE) does not need to be removed since it biodegrades completely.
In the unlikely event of Chlorhexidine Gluconate (Rexidin M FORTE) dislodgement (in the two pivotal clinical trials, only 8 chips were reported lost), several actions are recommended, depending on the day of Chlorhexidine Gluconate (Rexidin M FORTE) loss. If dislodgement occurs 7 days or more after placement, the dentist should consider the subject to have received a full course of treatment. If dislodgement occurs within 48 hours after placement, a new Chlorhexidine Gluconate (Rexidin M FORTE) should be inserted. If dislodgement occurs more than 48 hours after placement, the dentist should not replace the Chlorhexidine Gluconate (Rexidin M FORTE), but reevaluate the patient at 3 months and insert a new Chlorhexidine Gluconate (Rexidin M FORTE) if the pocket depth has not been reduced to less than 5 mm.
How suppliedChlorhexidine Gluconate (Rexidin M FORTE) (Chlorhexidine Gluconate (Rexidin M FORTE)) 2.5 mg is supplied as a small, orange-brown, rectangular chip (rounded at one end), in cartons of 20 chips (NDC 52096-001-22). Each chip is individually packed in a separate compartment of an aluminum blister pack.
Store at 20° - 25°C with excursions permitted to 15° - 30° C (59° - 86°F).
Manufactured by: Dexcel® Pharma Technologies Ltd, HaMarpeh 7 St.,Jerusalem 91237, Israel. Distributed by: Adrian Pharmaceuticals, Spring Hill, Florida 34606. Iss. 01/10
Important Dosage and Administration Instructions
Because of the difference in bioavailability of Lidocaine Topical (Rexidin M FORTE) compared to Lidocaine Topical (Rexidin M FORTE) (lidocaine patch 5%), a different dosage strength is required to be administered to the patient. One Lidocaine Topical (Rexidin M FORTE) (Lidocaine Topical (Rexidin M FORTE) system) 1.8% provides equivalent lidocaine exposure to one Lidocaine Topical (Rexidin M FORTE) (lidocaine patch 5%).
When Lidocaine Topical (Rexidin M FORTE) is used concomitantly with other products containing local anesthetic agents, the total amount of drug absorbed from all formulations must be considered.
Lidocaine Topical (Rexidin M FORTE) may not stick if it gets wet. Advise patients to avoid contact with water, such as bathing, swimming, or showering.
Instruct patients to wash hands immediately after handling Lidocaine Topical (Rexidin M FORTE) and to avoid contact with eyes.
Instruct patients to store Lidocaine Topical (Rexidin M FORTE) inside the sealed envelope and to apply immediately after removal from the envelope. Advise them to store Lidocaine Topical (Rexidin M FORTE) out of the reach of children, pets, and others. Instruct patients to, after use, fold used Lidocaine Topical (Rexidin M FORTE) so that the adhesive side sticks to itself and safely discard used Lidocaine Topical (Rexidin M FORTE) or pieces of cut Lidocaine Topical (Rexidin M FORTE) where children and pets cannot get to them.
Advise patients not to apply external heat sources, such as heating pads or electric blankets, directly to Lidocaine Topical (Rexidin M FORTE) because plasma lidocaine levels are increased. Lidocaine Topical (Rexidin M FORTE) can be applied, however, to the administration site after moderate heat exposure, such as 15 minutes of heating pad exposure on a medium setting.
Lidocaine Topical (Rexidin M FORTE) may be used during moderate exercise, such as biking for 30 minutes.
Lidocaine Topical (Rexidin M FORTE) topical systems that have lifted at the edges may be reattached by pressing firmly on the edges. If a Lidocaine Topical (Rexidin M FORTE) topical system comes off completely and will not stick to patient’s skin, it should be thrown away and a new Lidocaine Topical (Rexidin M FORTE) topical system should be applied for a total duration of 12 hours of used and new topical system together.
Post-herpetic Neuralgia
Apply Lidocaine Topical (Rexidin M FORTE) to intact skin to cover the most painful area. Apply the prescribed number of topical systems (maximum of 3), only once for up to 12 hours within a 24-hour period (12 hours on and 12 hours off). Lidocaine Topical (Rexidin M FORTE) may be cut into smaller sizes with scissors prior to removal of the release liner. Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination.
If irritation or a burning sensation occurs during application, advise patients to remove Lidocaine Topical (Rexidin M FORTE) and do not reapply until the irritation subsides.
Usual Adult Dose for Acne RosaceaMetronidazole Topical (Rexidin M FORTE) 1% gel or cream: Apply a thin film to the affected area once a day.
Metronidazole Topical (Rexidin M FORTE) 0.75% gel, cream, or lotion: Apply a thin film to the affected area twice a day.
Usual Adult Dose for Bacterial Vaginosis
Insert one applicatorful of Metronidazole Topical (Rexidin M FORTE) 0.75% vaginal gel intravaginally once (at bedtime) or twice a day for 5 consecutive days.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Gel, cream, lotion: Data not available
Vaginal gel: The manufacturer recommends caution when administering this drug to patients with severe hepatic disease.
Dose Adjustments
The duration of topical therapy is 4 to 10 weeks depending on the nature and severity of the condition.
Precautions
Patients should be advised to use Metronidazole Topical (Rexidin M FORTE) less frequently or discontinue use if a reaction suggesting local irritation occurs.
Convulsive seizures and peripheral neuropathy have been reported in patients receiving oral or IV metronidazole. If abnormal neurologic signs appear, Metronidazole Topical (Rexidin M FORTE) vaginal gel should be discontinued at once. The use of Metronidazole Topical (Rexidin M FORTE) 1% gel should be reevaluated at once if abnormal neurologic signs appear. Metronidazole Topical (Rexidin M FORTE) should be used with caution in patients with central nervous system diseases.
Metronidazole Topical (Rexidin M FORTE) should be used with caution in patients with evidence of, or history of blood dyscrasia.
Although disulfiram-like reactions have not been reported in patients receiving vaginal metronidazole, the manufacturer recommends that alcohol be avoided. Metronidazole Topical (Rexidin M FORTE) vaginal gel should not be used in patients who have taken disulfiram within the last 2 weeks.
Safety and efficacy have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
Other Comments
Metronidazole Topical (Rexidin M FORTE) may cause eye irritation if applied too close to the eyes. Contact with the eyes should be avoided.
Topical areas to be treated should be washed with a mild cleanser prior to application.
The manufacturer recommends avoidance of vaginal intercourse during treatment with Metronidazole Topical (Rexidin M FORTE) vaginal gel.
See also:
What other drugs will affect Chlorhexidine Gluconate (Rexidin M FORTE)?
Chlorhexidine Gluconate (Rexidin M FORTE) is incompatible with the soap, and detergents containing anionic group (saponins, sodium lauryl sulfate, sodium carboxymethyl cellulose).
Chlorhexidine Gluconate (Rexidin M FORTE) Pharmaniaga is compatible with any medication containing cationic group (cetrimonium bromide, benzalkonium chloride).
See also:
What other drugs will affect Lidocaine Topical (Rexidin M FORTE)?
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe prolonged hypotension or hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.
Concurrent administration of vasopressor drugs and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
As the 2% Lidocaine Topical (Rexidin M FORTE) DENTAL solutions both contain a vasoconstrictor (epinephrine), concurrent use of either with a Beta-adrenergic blocking agent (propranolol, timolol, etc.) may result in dosedependent hypertension and bradycardia with possible heart block.
Drug/Laboratory Test InteractionsThe intramuscular injection of lidocaine may result in an increase in creatine phosphokinase levels. Thus, the use of this enzyme determination, without isoenzyme separation, as a diagnostic test for the presence of acute myocardial infarction may be compromised by the intramuscular injection of lidocaine.
See also:
What other drugs will affect Metronidazole Topical (Rexidin M FORTE)?
The intravaginal administration of a single 5 gram dose of Metronidazole Topical (Rexidin M FORTE) results in relatively lower mean systemic exposure to metronidazole that is approximately 2% to 5% of that achieved following a 500 mg oral dose of metronidazole. The following drug interactions were reported for oral metronidazole.
DisulfiramUse of oral metronidazole has been associated with psychotic reactions in alcoholic patients who are using disulfiram concurrently. Metronidazole Topical (Rexidin M FORTE) (metronidazole vaginal gel) should not be used by patients who have taken disulfiram within the last two weeks.
Alcoholic BeveragesUse of oral metronidazole has been associated with a disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) to alcohol. Alcoholic beverages and preparations containing ethanol or propylene glycol should not be consumed during and for at least three days after Metronidazole Topical (Rexidin M FORTE) therapy.
Coumarin and OtherOral AnticoagulantsUse of oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when Metronidazole Topical (Rexidin M FORTE) (metronidazole vaginal gel) is prescribed for patients on this type of anticoagulant therapy. In patients on oral anticoagulants, consider monitoring prothrombin time, international normalized ratio (INR), and other coagulation parameters while on Metronidazole Topical (Rexidin M FORTE).
LithiumShort-term use of oral metronidazole has been associated with elevation of serum lithium concentrations and, in a few cases signs of lithium toxicity, in patients stabilized on relatively high doses of lithium. Use Metronidazole Topical (Rexidin M FORTE) (metronidazole vaginal gel) with caution in patients treated with lithium and consider monitoring lithium serum concentrations while on Metronidazole Topical (Rexidin M FORTE).
CimetidineUse of oral metronidazole with cimetidine may prolong the half-life and decrease plasma clearance of metronidazole. No dose adjustment of Metronidazole Topical (Rexidin M FORTE) (metronidazole vaginal gel) is necessary.